Rakuten Securities Inc. Has $84,000 Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Rakuten Securities Inc. boosted its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 68.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,355 shares of the company’s stock after purchasing an additional 550 shares during the period. Rakuten Securities Inc.’s holdings in TransMedics Group were worth $84,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of TMDX. Principal Financial Group Inc. boosted its position in TransMedics Group by 260.1% during the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock valued at $31,759,000 after purchasing an additional 146,115 shares during the last quarter. State of Michigan Retirement System acquired a new stake in TransMedics Group during the fourth quarter valued at $6,734,000. Public Sector Pension Investment Board acquired a new stake in TransMedics Group during the third quarter valued at $11,079,000. Connor Clark & Lunn Investment Management Ltd. boosted its position in TransMedics Group by 665.1% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 74,625 shares of the company’s stock valued at $11,716,000 after purchasing an additional 64,872 shares during the last quarter. Finally, Vaughan Nelson Investment Management L.P. boosted its position in TransMedics Group by 24.3% during the third quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock valued at $51,654,000 after purchasing an additional 64,360 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Trading Down 0.8 %

TransMedics Group stock opened at $67.08 on Thursday. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The business’s 50-day simple moving average is $68.64 and its 200-day simple moving average is $95.47. The firm has a market capitalization of $2.26 billion, a PE ratio of 71.36 and a beta of 2.12. TransMedics Group, Inc. has a 52 week low of $55.00 and a 52 week high of $177.37.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on TMDX shares. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $75.00 price target (down previously from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Piper Sandler reduced their price target on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research report on Wednesday, December 11th. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a research report on Wednesday, February 5th. Oppenheimer reaffirmed an “outperform” rating and issued a $125.00 price target on shares of TransMedics Group in a research report on Tuesday, December 3rd. Finally, TD Cowen reduced their price target on TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research report on Monday, November 18th. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $122.70.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.